Oramed Pharmaceuticals Inc. (ORMP): Price and Financial Metrics
ORMP Price/Volume Stats
| Current price | $2.61 | 52-week high | $13.73 |
| Prev. close | $2.51 | 52-week low | $1.81 |
| Day low | $2.51 | Volume | 78,100 |
| Day high | $2.64 | Avg. volume | 970,845 |
| 50-day MA | $3.09 | Dividend yield | N/A |
| 200-day MA | $3.60 | Market Cap | 105.12M |
ORMP Stock Price Chart Interactive Chart >
ORMP POWR Grades
- ORMP scores best on the Growth dimension, with a Growth rank ahead of 90.97% of US stocks.
- The strongest trend for ORMP is in Quality, which has been heading down over the past 177 days.
- ORMP ranks lowest in Quality; there it ranks in the 20th percentile.
ORMP Stock Summary
- With a one year PEG ratio of 0.62, ORAMED PHARMACEUTICALS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 6.75% of US stocks.
- With a price/sales ratio of 38.74, ORAMED PHARMACEUTICALS INC has a higher such ratio than 96.27% of stocks in our set.
- The volatility of ORAMED PHARMACEUTICALS INC's share price is greater than that of 95.55% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to ORMP, based on their financial statements, market capitalization, and price volatility, are LYEL, MRTX, PLRX, KRON, and SYNA.
- Visit ORMP's SEC page to see the company's official filings. To visit the company's web site, go to www.oramed.com.
ORMP Valuation Summary
- ORMP's price/sales ratio is 38.7; this is 867.5% higher than that of the median Healthcare stock.
- ORMP's EV/EBIT ratio has moved up 27.2 over the prior 199 months.
Below are key valuation metrics over time for ORMP.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ORMP | 2023-09-22 | 38.7 | 0.7 | -5.4 | -4.6 |
| ORMP | 2023-09-21 | 39.2 | 0.7 | -5.5 | -4.6 |
| ORMP | 2023-09-20 | 41.1 | 0.7 | -5.7 | -4.9 |
| ORMP | 2023-09-19 | 42.8 | 0.8 | -6.0 | -5.1 |
| ORMP | 2023-09-18 | 43.2 | 0.8 | -6.0 | -5.1 |
| ORMP | 2023-09-15 | 45.3 | 0.8 | -6.3 | -5.4 |
ORMP Growth Metrics
- Its year over year net cashflow from operations growth rate is now at -12.3%.
- The 4 year cash and equivalents growth rate now stands at 78.84%.
- Its 2 year net cashflow from operations growth rate is now at -27.73%.
The table below shows ORMP's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | NA | NA | NA |
| 2021-12-31 | 2.703 | -21.932 | -24.766 |
| 2021-09-30 | 2.703 | -21.181 | -22.238 |
| 2021-06-30 | 2.701 | -17.497 | -18.799 |
| 2021-03-31 | 2.701 | -15.216 | -15.458 |
| 2020-12-31 | 2.71 | -15.596 | -14.538 |
ORMP's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ORMP has a Quality Grade of D, ranking ahead of 13% of graded US stocks.
- ORMP's asset turnover comes in at 0.047 -- ranking 325th of 681 Pharmaceutical Products stocks.
- EDSA, RGEN, and STAB are the stocks whose asset turnover ratios are most correlated with ORMP.
The table below shows ORMP's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-05-31 | 0.047 | 1 | -0.870 |
| 2021-02-28 | 0.056 | 1 | -0.619 |
| 2020-11-30 | 0.067 | 1 | -0.614 |
| 2020-08-31 | 0.071 | 1 | -0.461 |
| 2020-05-31 | 0.076 | 1 | -0.408 |
| 2020-02-29 | 0.081 | 1 | -0.501 |
ORMP Price Target
For more insight on analysts targets of ORMP, see our ORMP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $23.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
Oramed Pharmaceuticals Inc. (ORMP) Company Bio
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company was founded in 2002 and is based in Jerusalem, Israel.
Latest ORMP News From Around the Web
Below are the latest news stories about ORAMED PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORMP as an investment opportunity.
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding CompanySorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, "Scilex") of certain securities that Sorrento held in Scilex. |
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanyOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE:ORMP) today announced that on September 21, 2023, Oramed and Scilex Holding Company ("Scilex") entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note (the "Note") to Oramed. The Note is the culmination of Scilex's assumption of Sorrento Therapeutics Inc.'s ("Sorrento") approximately $100 million senior secured Debtor In Possession ("DIP") term loan facility with Oramed. Oramed previously annou |
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”). Pursuant to that certain Stock Purchase Agreement entered into on Septem |
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful BidderPALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non |
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyOramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) announced today that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. ("HTIT") to establish a joint venture ("JV") based on Oramed's oral drug delivery technology. The proposed JV would focus on the development and worldwide commercialization of innovative products based on Oramed's oral insulin and POD™ (Protein Oral Delivery) pipeline and HTIT's manufacturing capabilities and technologies. The J |
ORMP Price Returns
| 1-mo | -24.13% |
| 3-mo | -26.27% |
| 6-mo | 20.83% |
| 1-year | -59.72% |
| 3-year | 2.76% |
| 5-year | -44.82% |
| YTD | -78.30% |
| 2022 | -15.76% |
| 2021 | 236.79% |
| 2020 | -17.67% |
| 2019 | 71.67% |
| 2018 | -66.67% |
Continue Researching ORMP
Want to see what other sources are saying about Oramed Pharmaceuticals Inc's financials and stock price? Try the links below:Oramed Pharmaceuticals Inc (ORMP) Stock Price | Nasdaq
Oramed Pharmaceuticals Inc (ORMP) Stock Quote, History and News - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...